Compare iShares MSCI Indonesia ETF (EIDO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Moderna, Inc. — how do they compare? iShares MSCI Indonesia ETF trades at $12.68, while Moderna, Inc. trades at $64.05 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| EIDO | MRNA | |
|---|---|---|
52-Week High | $19.22 | $81.80 |
52-Week Low | $10.80 | $22.36 |
Market Cap | — | $24.18B |
Sector | — | Health |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO, the iShares MSCI Indonesia ETF, trades at $12.675, down 0.59% today, with a bearish technical signal from moving averages. The fund's valuation appears low, but financial data for the current period is unavailable. Recent news highlights Indonesia's economic initiatives and central bank policy shifts, while technical indicators show neutral oscillators and defined support at $12.
The outlook is mixed, with potential from Indonesia's GDP growth initiatives but weighed by foreign capital outflows and a strong financials weighting. Risks include currency volatility and dependence on commodity markets. Analyst sentiment is neutral due to weak price action despite attractive valuations.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
